Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas.

ABSTRACT:

SUBMITTER: Nicolae A

PROVIDER: S-EPMC7701980 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas.

Nicolae A A Xi L L Pittaluga S S Abdullaev Z Z Pack S D SD Chen J J Waldmann T A TA Jaffe E S ES Raffeld M M

Leukemia 20140620 11

PMID: 24947020

Similar Datasets

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.

Project description: Not available

| S-EPMC7743911 | biostudies-literature

A STAT5B-driven mouse model of hepatosplenic γδ T cell lymphoma reveals therapeutic efficacy of JAK inhibitors

Project description:Hepatosplenic T cell lymphoma (HSTL) is a rare, aggressive disease primarily affecting young adults. The disease progresses rapidly, with patients displaying low survival rates and poor responses to standard chemotherapy-based treatments. Currently no targeted therapies are available for HSTL, and pre-clinical models to test new treatment options have not been established. Hence, new models recapitulating HSTL are needed. The JAK-STAT signalling pathway is a key pathway dysregulated in HSTL and STAT5B N642H is the most frequent oncogenic mutation. Using a transgenic mouse model, we have previously validated STAT5B N642H as a strong driver of γδ T cell lymphoma. Here, we have established clonal, murine γδ T cell lymphoma cell lines driven by oncogenic STAT5B, which resemble key features of human HSTL. The IL-2 dependent cell line, C15, displays immunophenotypic features as well as commonly dysregulated gene expression profiles shared with patient-derived HSTL cell lines. C15 cells can be engrafted intravenously into immunocompetent mice to generate an aggressive HSTL-like disease. Recipient mice display an expansion of malignant γδ T cells causing hepatosplenomegaly and elevated alanine transaminase (ALT) and aspartate transaminase (AST) levels. Using these models, we tested the potential of JAK inhibition as a targeted treatment strategy for HSTL, with the clinically-approved JAK inhibitor upadacitinib displaying significant anti-tumor efficacy against HSTL cells in vitro and in vivo. Overall, we have developed a robust, accessible and faithful preclinical model of HSTL with the advantage of immune-competence, which can facilitate the study of physiological disease mechanisms and new (immuno)therapy strategies.

2026-03-12 | GSE271616 | GEO

Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression.

Project description: Not available

| S-EPMC9947078 | biostudies-literature

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.

Project description: Not available

| S-EPMC8025136 | biostudies-literature

Nonhepatosplenic γδ T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation.

Project description: Not available

| S-EPMC3136885 | biostudies-literature

Addiction of primary cutaneous γδ T cell lymphomas to JAK/STAT signaling.

Project description: Not available